Fifth Third Bancorp Boosts Stock Holdings in Humana Inc. $HUM

Key Points

• Fifth Third Bancorp increased its stake in Humana Inc. by 18.7%, now holding 9,768 shares worth approximately $2.39 million after adding 1,540 shares in the second quarter.
• Humana reported earnings of $6.27 per share for its latest quarter, falling short of analysts' expectations but achieving a 9.6% year-over-year revenue growth of $32.39 billion.
• The company has announced a quarterly dividend of $0.885 per share, set to be paid on October 31st, providing an annualized yield of 1.4% with a payout ratio of 27.17%.

Fifth Third Bancorp lifted its position in Humana Inc. (NYSE:HUM - Free Report) by 18.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 9,768 shares of the insurance provider's stock after acquiring an additional 1,540 shares during the quarter. Fifth Third Bancorp's holdings in Humana were worth $2,388,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its stake in Humana by 8.9% in the 1st quarter. Vanguard Group Inc. now owns 13,972,872 shares of the insurance provider's stock valued at $3,697,222,000 after buying an additional 1,143,662 shares during the last quarter. AQR Capital Management LLC increased its position in shares of Humana by 3,257.5% during the first quarter. AQR Capital Management LLC now owns 1,162,600 shares of the insurance provider's stock valued at $307,624,000 after acquiring an additional 1,127,973 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Humana by 40,881.1% during the first quarter. GAMMA Investing LLC now owns 781,099 shares of the insurance provider's stock valued at $2,066,790,000 after acquiring an additional 779,193 shares during the last quarter. Nuveen LLC bought a new stake in Humana during the first quarter worth $171,220,000. Finally, Dodge & Cox boosted its position in Humana by 5.5% in the first quarter. Dodge & Cox now owns 10,755,215 shares of the insurance provider's stock worth $2,845,830,000 after purchasing an additional 557,175 shares during the last quarter. 92.38% of the stock is owned by institutional investors.

Humana Stock Performance

Shares of HUM stock opened at $254.72 on Friday. The firm's 50 day moving average is $271.91 and its 200 day moving average is $257.31. The stock has a market capitalization of $30.64 billion, a P/E ratio of 19.55, a PEG ratio of 1.50 and a beta of 0.44. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $324.38. The company has a current ratio of 1.95, a quick ratio of 1.95 and a debt-to-equity ratio of 0.69.

Humana (NYSE:HUM - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to analysts' expectations of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. The firm's quarterly revenue was up 9.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $6.96 earnings per share. Humana has set its FY 2025 guidance at 17.000- EPS. On average, sell-side analysts anticipate that Humana Inc. will post 16.47 earnings per share for the current year.

Humana Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $3.54 dividend on an annualized basis and a yield of 1.4%. Humana's dividend payout ratio is 27.17%.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on HUM shares. Sanford C. Bernstein lifted their target price on Humana from $269.00 to $341.00 and gave the stock an "outperform" rating in a research note on Friday, September 5th. Morgan Stanley lowered their price objective on shares of Humana from $290.00 to $277.00 and set an "equal weight" rating on the stock in a research report on Thursday, July 31st. Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. Truist Financial lowered their price target on shares of Humana from $280.00 to $260.00 and set a "hold" rating on the stock in a report on Wednesday, July 16th. Finally, Robert W. Baird reduced their price objective on Humana from $300.00 to $297.00 and set a "neutral" rating for the company in a report on Friday, July 25th. Seven research analysts have rated the stock with a Buy rating and seventeen have assigned a Hold rating to the stock. According to data from MarketBeat, Humana has an average rating of "Hold" and an average price target of $289.50.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.